(Q43660892)

English

Plasma Stability-Dependent Circulation of Acyl Glucuronide Metabolites in Humans: How Circulating Metabolite Profiles of Muraglitazar and Peliglitazar Can Lead to Misleading Risk Assessment

scientific article published on September 28, 2010

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Plasma stability-dependent circulation of acyl glucuronide metabolites in humans: how circulating metabolite profiles of muraglitazar and peliglitazar can lead to misleading risk assessment (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Plasma Stability-Dependent Circulation of Acyl Glucuronide Metabolites in Humans: How Circulating Metabolite Profiles of Muraglitazar and Peliglitazar Can Lead to Misleading Risk Assessment (English)

1 reference

10.1124/DMD.110.035048

https://api.crossref.org/works/10.1124/DMD.110.035048

22 July 2024

author name string

Donglu Zhang

1

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Nirmala Raghavan

2

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Lifei Wang

3

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Yongjun Xue

4

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Mary Obermeier

5

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Stephanie Chen

6

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Shiwei Tao

7

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Hao Zhang

8

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Wenying Li

10

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Ragu Ramanathan

11

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Zheng Yang

12

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Peter T. Cheng

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20876787

22 July 2024

W. Griffith Humphreys

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20876787

22 July 2024

language of work or name

1 reference

based on heuristic

inferred from title

publication date

28 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

full work available at URL

http://intl-dmd.aspetjournals.org/cgi/content/abstract/39/1/123

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20876787

22 July 2024

https://syndication.highwire.org/content/doi/10.1124/dmd.110.035048

1 reference

10.1124/DMD.110.035048

https://api.crossref.org/works/10.1124/DMD.110.035048

22 July 2024

Drug Metabolism and Disposition

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

39

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

123-131

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Stereoselective internal acyl migration of 1beta-O-acyl glucuronides of enantiomeric 2-phenylpropionic acids.

1

1 reference

10.1124/DMD.110.035048

https://api.crossref.org/works/10.1124/DMD.110.035048

22 July 2024

Rapid internal acyl migration and protein binding of synthetic probenecid glucuronides

2

1 reference

10.1124/DMD.110.035048

https://api.crossref.org/works/10.1124/DMD.110.035048

22 July 2024

Acyl glucuronide reactivity in perspective: biological consequences

3

1 reference

10.1124/DMD.110.035048

https://api.crossref.org/works/10.1124/DMD.110.035048

22 July 2024

Drug metabolites in safety testing

4

1 reference

10.1124/DMD.110.035048

https://api.crossref.org/works/10.1124/DMD.110.035048

22 July 2024

HPLC/1H NMR spectroscopic studies of the reactive alpha-1-O-acyl isomer formed during acyl migration of S-naproxen beta-1-O-acyl glucuronide

5

1 reference

10.1124/DMD.110.035048

https://api.crossref.org/works/10.1124/DMD.110.035048

22 July 2024

Disposition and chemical stability of telmisartan 1-O-acylglucuronide

6

1 reference

10.1124/DMD.110.035048

https://api.crossref.org/works/10.1124/DMD.110.035048

22 July 2024

Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity

7

1 reference

10.1124/DMD.110.035048

https://api.crossref.org/works/10.1124/DMD.110.035048

22 July 2024

Kinetics of intramolecular acyl migration of 1beta-O-acyl glucuronides of (R)- and (S)-2-phenylpropionic acids.

9

1 reference

10.1124/DMD.110.035048

https://api.crossref.org/works/10.1124/DMD.110.035048

22 July 2024

Safety assessment of drug metabolites: Characterization of chemically stable metabolites

10

1 reference

10.1124/DMD.110.035048

https://api.crossref.org/works/10.1124/DMD.110.035048

22 July 2024

Syntheses and characterization of the acyl glucuronide and hydroxy metabolites of diclofenac

12

1 reference

10.1124/DMD.110.035048

https://api.crossref.org/works/10.1124/DMD.110.035048

22 July 2024

Species differences in the elimination of a peroxisome proliferator-activated receptor agonist highlighted by oxidative metabolism of its acyl glucuronide

13

1 reference

10.1124/DMD.110.035048

https://api.crossref.org/works/10.1124/DMD.110.035048

22 July 2024

Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide

14

1 reference

10.1124/DMD.110.035048

https://api.crossref.org/works/10.1124/DMD.110.035048

22 July 2024

LC-1H NMR used for determination of the elution order of S-naproxen glucuronide isomers in two isocratic reversed-phase LC-systems

15

1 reference

10.1124/DMD.110.035048

https://api.crossref.org/works/10.1124/DMD.110.035048

22 July 2024

Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions

16

1 reference

10.1124/DMD.110.035048

https://api.crossref.org/works/10.1124/DMD.110.035048

22 July 2024

Effective synthesis of 1beta-acyl glucuronides by selective acylation

17

1 reference

10.1124/DMD.110.035048

https://api.crossref.org/works/10.1124/DMD.110.035048

22 July 2024

Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism?

19

1 reference

10.1124/DMD.110.035048

https://api.crossref.org/works/10.1124/DMD.110.035048

22 July 2024

Acyl glucuronides: biological activity, chemical reactivity, and chemical synthesis

20

1 reference

10.1124/DMD.110.035048

https://api.crossref.org/works/10.1124/DMD.110.035048

22 July 2024

Acyl glucuronide drug metabolites: toxicological and analytical implications

21

1 reference

10.1124/DMD.110.035048

https://api.crossref.org/works/10.1124/DMD.110.035048

22 July 2024

Glucuronidation as a major metabolic clearance pathway of 14c-labeled muraglitazar in humans: metabolic profiles in subjects with or without bile collection

22

1 reference

10.1124/DMD.110.035048

https://api.crossref.org/works/10.1124/DMD.110.035048

22 July 2024

Metabolism and disposition of 14C-labeled peliglitazar in humans

23

1 reference

10.1124/DMD.110.035048

https://api.crossref.org/works/10.1124/DMD.110.035048

22 July 2024

Optimization to eliminate the interference of migration isomers for measuring 1-O-beta-acyl glucuronide without extensive chromatographic separation

24

1 reference

10.1124/DMD.110.035048

https://api.crossref.org/works/10.1124/DMD.110.035048

22 July 2024

In vitro and in vivo metabolism of a gamma-secretase inhibitor BMS-299897 and generation of active metabolites in milligram quantities with a microbial bioreactor

25

1 reference

10.1124/DMD.110.035048

https://api.crossref.org/works/10.1124/DMD.110.035048

22 July 2024

Metabolism, pharmacokinetics, and protein covalent binding of radiolabeled MaxiPost (BMS-204352) in humans

26

1 reference

10.1124/DMD.110.035048

https://api.crossref.org/works/10.1124/DMD.110.035048

22 July 2024

LC-MS/MS-based approach for obtaining exposure estimates of metabolites in early clinical trials using radioactive metabolites as reference standards

27

1 reference

10.1124/DMD.110.035048

https://api.crossref.org/works/10.1124/DMD.110.035048

22 July 2024

Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling

28

1 reference

10.1124/DMD.110.035048

https://api.crossref.org/works/10.1124/DMD.110.035048

22 July 2024

Integrated strategies for assessment of metabolite exposure in humans during drug development: analytical challenges and clinical development considerations.

29

1 reference

10.1124/DMD.110.035048

https://api.crossref.org/works/10.1124/DMD.110.035048

22 July 2024

Identifiers

10.1124/DMD.110.035048

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43660892&oldid=2209916080"